Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Approvals Commercial FDA

Horizon Sees Blockbuster Future For Tepezza After US Approval

First Treatment For Thyroid Eye Condition

Executive Summary

Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.

You may also be interested in...



Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence

The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.

AstraZeneca’s Next-Gen PARP Inhibitor Hints At Better Safety And Efficacy In Breast Cancer

Early signs of improved safety and efficacy should set up PARP1 inhibitor for potential combinations and future broader use, but the true extent of its benefits remain to be seen.

Table

View full table

Topics

Related Companies

Tags:
Approvals Commercial FDA
Latest Headlines

China VBP, Localization And Other Strategies - How Far And Which Way?

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

With One Launch Under Way, SpringWorks Ramps Up For A Second

Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar

See All
UsernamePublicRestriction

Register

SC141508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By